Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Other Non-Current Liabilities (2022 - 2025)

Envoy Medical's Other Non-Current Liabilities history spans 4 years, with the latest figure at $891000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 14750.0% year-over-year to $891000.0; the TTM value through Sep 2025 reached $891000.0, up 14750.0%, while the annual FY2024 figure was $472000.0, 75.46% down from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $891000.0 at Envoy Medical, down from $1.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.8 million in Q1 2024 and bottomed at $6000.0 in Q3 2024.
  • The 4-year median for Other Non-Current Liabilities is $891000.0 (2025), against an average of $1.1 million.
  • The largest annual shift saw Other Non-Current Liabilities crashed 99.53% in 2024 before it skyrocketed 14750.0% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $127000.0 in 2022, then skyrocketed by 1414.17% to $1.9 million in 2023, then plummeted by 75.46% to $472000.0 in 2024, then surged by 88.77% to $891000.0 in 2025.
  • Per Business Quant, the three most recent readings for COCH's Other Non-Current Liabilities are $891000.0 (Q3 2025), $1.7 million (Q2 2025), and $891000.0 (Q1 2025).